Video

Dr. Singal on Downstaging Strategies in HCC

Amit Singal, MD, discusses downstaging strategies for patients with hepatocellular carcinoma.

Amit Singal, MD, medical director of the Liver Tumor Program and clinical chief of hepatology at the University of Texas Southwestern Medical Center, discusses downstaging strategies for patients with hepatocellular carcinoma (HCC).

When patients present within the traditional Milan Criteria for Liver Transplant in the United States, disease management is straightforward, according to Singal. Patients who fall within these criteria have excellent long-term survival, Singal says. Along with recognizing the patients who were achieving long-term survival, the HCC community has also begun to acknowledge that those with larger intrahepatic tumor burden could be downstaged, Singal notes.

This can be achieved through locoregional therapies, which can help patients to fall within criteria after achieving a response to treatment. Some of these approaches include chemotherapy embolization, radiotherapy embolization, or stereotactic body radiation therapy, Singal notes. Patients who have been downstaged after responding to treatment are able to achieve excellent long-term survival that is on par with those who started and stayed within criteria, Singal concludes.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University